Immune responses to p53 in patients with cancer:enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites

Cancer Immunology, Immunotherapy

Volumn 54, Issue 11, 2005, Pages 1072-1081

  Albers, Andreas E ^a   Ferris, Robert L ^b   Kim, Grace G ^a   Chikamatsu, Kazuaki ^a   DeLeo, Albert B ^b   Whiteside, Theresa L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

CD4+CD25+ T cells; Regulatory T cells (Treg); Tetramers; TIL; Tumor escape; wt p53 epitopes

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; PEPTIDE; PROTEIN P53; TETRAMER; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CELL POPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE RESPONSE; MALE; MICROENVIRONMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; DNA-BINDING PROTEINS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 25844435263     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0670-9     Document Type: Article

References (32)

1. Chikamatsu K, Nakano K, Storkus WJ, Appell E, Lotze MT, Whiteside TL, DeLeo AB (1999) Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 5:1281
2. Curiel TJ, Coukos G, Zou L, Alvarez X, et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942
3. Elder EM, Whiteside TL (1992) Processing of tumors for vaccine and/or tumor infiltrating lymphocytes. In: Friedman H, Rose NR, deMacario EC, Fahey JL, Friedman H, Penn GM (Eds) Manual of clinical laboratory immunology, vol 123, 4th edn. American Society of Microbiology, Washington, p 817
4. Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet J-G, Choppin J (1998) Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol 160:328
5. Harris CC (1996) Structure and function of the p53 tumor suppressor gene: clues and rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442
6. Herrin V, Behrens RJ, Achtar M, Monahan B, Bernstein S, Brent-Steele T, Whiteside T, Wieckowski E, Berzofsky J, Khleif SN (2003) Wild-type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinoma. Abstr 678 Proc Am Soc Clin Oncol 22:169
7. 264-272 peptide in cancer patients - implications for immunoselection of epitope-loss variants. J Immunol 165:5938
8. 264-272 peptide in the circulations of patients with head and neck cancer. Cancer Res 62:3521
9. Hoffmann TK, Donnenberg V, Friebe-Hoffmann U, Meyer M, Rinaldo CR, DeLeo AB, Whiteside TL, and Donnenberg AD (2000) Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex. Cytometry 41:321
10. Hoffmann TK, Dworacki G, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL (2002) Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8:2553
11. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49
12. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC (1996) Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 24:141
13. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH (2001) Identification and functional characterization of human CD4+ CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med 193:1285
14. Lee KM, Chuang E, Griffin M, et al (1998) Molecular basis of T cell inactivation by CTLA-4. Science 282:2263
15. Letessier E, Sacchi M, Johnson JT, Herberman RB, Whiteside TL (1990) The absence of lymphoid suppressor cells in tumor-involved lymph nodes of patients with head and neck cancer. Cell Immunol 130:446
16. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756
17. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181
18. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD, Isaacs JD, Lechler RI (2001) Human CD4+ CD25+ cells: a naturally occurring population of regulatory T cells. Blood 98:2736
19. Ramsdell F (2003) Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 19:165
20. Raybaud-Diogene H, Tetu B, Morency R, Fortin A, Monteil R (1996) p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Eur J Cancer B Oral Oncol 32b:143
21. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL (2002) Signaling abnormalities and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 8:3137
22. Ronchetti S, Zollo O, Bruscoll S, Agostini M, Bianchini R, Nocentini G, Ayroldi E, Riccardi C (2004) GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol 34:613
23. Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL (2005) Characteristics of CD4+ CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92:913
24. Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211
25. Soussi T (1996) The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for the diagnosis and therapy. Immunol Today 17:354
26. Shevach EM (2004) Fatal attraction: tumors becon regulatory T cells. Nat Med 10:900
27. Stephens GL, McHugh RS, Whitters MJ, Young DA et al (2004) Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+ CD25+ T cells. J Immunol 173:5008
28. Tsukishiro T, Donnenberg AD, Whiteside TL (2003) Rapid turnover of the CD8+ CD28- T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother 52:599
29. Whiteside TL (2002) Tumor-induced death of immune cells: its mechanisms and consequences. Sem Cancer Biol 12:43
30. Whiteside TL, Rabinowich H (1998) The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 46:175
31. Wolf AM, Wolf D, Steurer M, Gasti G, Gunsilius E, Grubeckloebenstein B (2003) Increase in regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606
32. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH (2001) Regulatory CD4+ CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766